Medrx News

Medrx: Notice regarding the recording of non-operating expenses

Nov 8 01:30 ET

Medrx: Summary of Financial Results for the 3rd Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)

Nov 8 01:30 ET

Medrx: Notice regarding the monthly exercise status of the 29th Stock Acquisition Rights (with exercise price amendment clause) issued by third party allotment

Oct 31 19:50 ET

Medrx: Notice of commencement of MRX-7MLL clinical trials

Oct 28 02:00 ET

Medrx: Notice regarding the monthly exercise status of the 29th Stock Acquisition Rights (with exercise price amendment clause) issued by third party allotment

Sep 30 19:50 ET

Medrx: Notice Concerning Mass Exercise of the 29th Stock Acquisition Rights (with Exercise Price Amendment Clauses) Issued by Third Party Allotment

Sep 24 03:00 ET

Medrx: Notice regarding the Reiwa 6th SME Overseas Expansion Support Project Cost Subsidy (Overseas Application Support Project) Indirect Subsidy Grant Decision

Sep 24 02:00 ET

Medrx: Notice of Patent Assessment (Japan) relating to MRX-4TZT

Sep 5 04:00 ET

Medrx: Change Report (short-term mass transfer)

Sep 3 23:09 ET

Medrx: Notice regarding the monthly exercise status of the 29th Stock Acquisition Rights (with exercise price amendment clause) issued by third party allotment

Sep 1 19:50 ET

Medrx: Change Report

Aug 26 00:57 ET

Medrx: Financial results presentation for the second quarter of the fiscal year ending December 2024.

Aug 21 19:50 ET

Medrx: Change Report

Aug 21 00:04 ET

Medrx: Announcement of the massive exercise of the 29th subscription rights (with an exercise price adjustment clause) issued by third-party allotment.

Aug 19 03:00 ET

Medrx: Change Report

Aug 14 23:36 ET

Medrx: Announcement of the massive exercise of the 29th subscription rights (with an exercise price adjustment clause) issued by third-party allotment.

Aug 14 03:00 ET

Medrx: Confirmatory letter.

Aug 9 02:01 ET

Medrx: Announcements of individual stocks regarding the modification clause of the exercise price by third-party allocation and the 25th, 28th, and 29th subscription rights, and the change in the expected timing of expenditure of procurement funds.

Aug 9 02:00 ET

Medrx: Announcement of differences between financial estimates and actual results for the second quarter (interim period) of the fiscal year ending December 2024.

Aug 9 02:00 ET

Medrx: Announcements of individual stocks regarding the recognition of non-operating income, non-operating expenses and special profits

Aug 9 02:00 ET